Literature DB >> 15201959

Criteria for predicting the recurrence and metastasis of stage I and II gastric cancer without lymph node metastasis.

Masaya Mukai1, Shinkichi Sato, Tomomi Kimura, Nobukazu Komatsu, Hiromi Ninomiya, Hisao Nakasaki, Kyouji Ogoshi, Hiroyasu Makuuchi.   

Abstract

This study examined whether detection of occult neoplastic cells (ONCs) in lymph nodes or the high-risk criteria for recurrence/metastasis of colorectal cancer were useful for predicting the recurrence of primary gastric cancer. The subjects were 122 patients with node-negative stage I or stage II primary gastric cancer. Prediction of recurrence using ONCs showed a sensitivity of 25.0% (2/8), specificity of 97.1% (100/103), and accuracy of 61.1% in stage I patients, while the respective values were 75.0% (3/4), 100.0% (7/7), and 87.5% in stage II patients. Prediction of recurrence in patients who fulfilled 2 or more of the high-risk criteria showed a sensitivity of 37.5% (3/8), specificity of 94.2% (97/103), and accuracy of 65.9% for stage I patients, while the respective values were 100.0% (4/4), 85.7% (6/7), and 92.9% for stage II patients. These results suggest that the prediction of recurrence based on the high-risk criteria shows a high sensitivity, specificity, and accuracy in patients of stage II gastric cancer without lymph node metastasis.

Entities:  

Mesh:

Year:  2004        PMID: 15201959

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Significance of occult neoplastic cells on tumor metastasis: a case report of gastric cancer.

Authors:  Shinkichi Sato; Masaya Mukai
Journal:  Diagn Pathol       Date:  2010-02-24       Impact factor: 2.644

2.  Occult neoplastic cells in lymph node sinuses and recurrence/metastasis of stage II/III gastric cancer.

Authors:  Yasutomo Sekido; Masaya Mukai; Masashi Yamazaki; Takayuki Tajima; Souichirou Yamamoto; Sayuri Hasegawa; Kyoko Kishima; Takuma Tajiri; Naoya Nakamura
Journal:  Oncol Lett       Date:  2013-11-06       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.